Production (Stage)
D
Arcutis Biotherapeutics, Inc. ARQT
$13.98 $0.322.34% NASDAQ
Recommendation
Prev Close
$13.98
Volume
1,646,232
Avg Vol (90D)
2,349,945
Market Cap
$1.67B
Dividend & Yield
--
52-Week Range
$6.99 - $17.75
P/E (TTM)
--
EPS (TTM)
-$1.04
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Buys $34,423.20 in Stock
5/24/2025 - MarketBeat
Analyst Expectations For Arcutis Biotherapeutics's Future
5/23/2025 - Benzinga
Arcutis Biotherapeutics (ARQT, $13.76) Moving Average Convergence Divergence (MACD) Histogram turned negative on May 22, 2025
5/23/2025 - Tickeron - Stocks
Arcutis Biotherapeutics Inc (ARQT) Announces FDA Approval for ZORYVE Foam for Plaque Psoriasis ...
5/22/2025 - GuruFocus
FDA Approval Boosts Arcutis Biotherapeutics (ARQT) with New Psoriasis Treatment ARQT Stock News
5/22/2025 - GuruFocus
Arcutis Biotherapeutics reports FDA approves sNDA for Zoryve topical foam
5/22/2025 - TipRanks Financial Blog
Arcutis Biotherapeutics reports FDA approves sNDA for Zoryve topical foam
5/22/2025 - The Fly
Arcutis' ZORYVE (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
5/22/2025 - Globe Newswire
Rafferty Asset Management LLC Trims Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
5/22/2025 - MarketBeat
Arcutis Biotherapeutics (ARQT, $13.76) Stochastic Oscillator left the overbought zone on May 21, 2025
5/22/2025 - Tickeron - Stocks
Arcutis Biotherapeutics (ARQT, $14.51) entered Uptrend as Momentum indicator ascends above 0 level on May 20, 2025
5/21/2025 - Tickeron - Technical Analysis
Arcutis Biotherapeutics (ARQT, $14.51) Stochastic Oscillator left the overbought zone on May 20, 2025
5/21/2025 - Tickeron - Technical Analysis
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $104,835.57 in Stock
5/21/2025 - MarketBeat
64,183 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Acquired by Focus Partners Wealth
5/21/2025 - MarketBeat
Suvretta Capital Management LLC Raises Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
5/19/2025 - MarketBeat
Point72 Asset Management L.P. Acquires 1,509,136 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
5/19/2025 - MarketBeat
Lazard Asset Management LLC Lowers Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
5/18/2025 - MarketBeat
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
5/15/2025 - Globe Newswire
Cubist Systematic Strategies LLC Invests $1.79 Million in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
5/15/2025 - MarketBeat
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Price T Rowe Associates Inc. MD
5/15/2025 - MarketBeat
Balyasny Asset Management L.P. Makes New Investment in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
5/14/2025 - Ticker Report
D. E. Shaw & Co. Inc. Buys 768,553 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
5/13/2025 - MarketBeat
HC Wainwright Has Bullish Estimate for ARQT Q2 Earnings
5/11/2025 - MarketBeat
Ensign Peak Advisors Inc Has $33.07 Million Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
5/11/2025 - Ticker Report
Equities Analysts Set Expectations for ARQT Q1 Earnings
5/10/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$212.82M
EBITDA (TTM)
-$115.93M
EBIT (TTM)
-$121.30M
Net Income (TTM)
-$129.72M
Balance Sheet
Total Assets (Q)
$344.11M
Total Debt (Q)
$110.80M
Total Liabilities (Q)
$201.45M
Book Value Per Share (Q)
$1.20
Cash Flow
Cash from Operations (TTM)
-$110.94M
Cash from Investing (TTM)
$69.27M
Cash from Financing (TTM)
-$95.17M
Net Change in Cash (TTM)
-$136.99M
Filings
Filing Date
Tuesday, May 6, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
1.59
7-Day Total Return
2.57%
30-Day Total Return
11.04%
60-Day Total Return
2.12%
90-Day Total Return
0.43%
Year to Date Total Return
-3.98%
1-Year Total Return
52.62%
2-Year Total Return
55.51%
3-Year Total Return
-37.03%
5-Year Total Return
-53.32%
52-week Low
Jun 10, 2024 - $6.99
52-week High
Mar 25, 2025 - $17.75
Valuation
Market Cap
$1.67B - Small Cap
Enterprise Value
$1.58B
Price/Sales (TTM)
8.28
Price/Book (Q)
11.68
Dividends and Shares
Shares Outstanding
126.04M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.arcutis.com
Phone Number
805 418 5006
Address
3027 Townsgate Road
Westlake Village, CA 91361
Country
United States
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed